Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel

Tuesday, August 5, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

WEIFANG, Shandong, China, Aug. 4 ShengtaiPharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or"the Company"), a leading manufacturer and distributor of high-quality,pharmaceutical grade glucose products in China, today announced that it hasretained Grayling Global to lead a strategic communications program ("the IRprogram") to shareholders, the investment community and financial media.

As the investor relations counsel for Shengtai Pharmaceutical, GraylingGlobal will help raise the investment community's awareness of the Company'sperformance through timely corporate updates, direct communications with fundmanagers, financial media placements and investor conference presentations."We are pleased to have a global IR network and its senior counselors withlong standing healthcare and industrial track records to help us raise ourfinancial profile and ensure the full understanding of our business model andexciting growth prospects," said Mr. Qingtai Liu, Chief Executive Officer ofShengtai Pharmaceutical. "We need to increase our visibility and expand ourrelationships with U.S. investors. As we are becoming a bigger company andplanning to move onto main exchange, we believe Grayling Global is best suitedto guide this investor relations process."

Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), isheadquartered in London, with offices in New York, Brussels, Bangkok,Singapore, Madrid, Moscow, Tel Aviv, Hong Kong, Istanbul, Los Angeles,Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm hasover 200 consultants, focusing on first-class delivery in public affairs,public relations, investor relations and events management.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary ShengtaiHolding, Inc. (SHI), a New Jersey corporation, and the Chinese operatingcompany of Weifang Shengtai Pharmaceutical Co., Ltd., is a leadingmanufacturer and supplier of pharmaceutical grade glucose used for medicalpurposes, and the glucose and cornstarch products for the food and beverageindustry and for industrial production in China. For more information aboutShengtai Pharmaceutical, Inc., please visit .

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Actof 1995: Certain statements in this press release and oral statements made bythe Company constitute forward-looking statements for purposes of the safeharbor provisions under The Private Securities Litigation Reform Act of 1995.These statements include, without limitation, statements regarding our abilityto prepare the company for growth, the Company's planned capacity expansion in2008 and predictions and guidance relating to the Company's future financialperformance. We have based these forward-looking statements largely on ourcurrent expectations and projections about future events and financial trendsthat we believe may affect our financial condition, results of operations,business strategy and financial needs but they involve risks and uncertaintiesthat could cause actual results to differ materially from those in theforward-looking statements, which may include, but are not limited to, suchfactors as unanticipated changes in product demand especially in thepharmaceutical industry, pricing and demand trends for the Company's products,changes to government regulations, risk associated with operation of theCompany's new facilities, risk associated with large scale implementation ofthe company's business plan, the ability to attract new customers, ability toincrease its product's applications, cost of raw materials, downturns in theChinese economy, and other information detailed from time to time in theCompany's filings and future filings with the United States Securities andExchange Commission. Investors are urged to co

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store